Aspire Biopharma

ASBP

Market cap $5.83M

Collaboration aims to create the first-ever sublingual alprazolam powder, addressing the need for faster-acting anxiety medication. Phase 1 clinical trial of the patent-pending, rapid-onset formulation planned for mid-2026.

BUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival. ESTERO, FL / ACCESS Newswire / February 25, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced a massive expansion of its social media and digital marketing footprint for its wholly owned subsidiary, Buzz Bomb Caffeine Company.

Company achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed Aspire maintains listing on the Nasdaq ESTERO, FL / ACCESS Newswire / February 20, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it had received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that the Company has regained compliance with the minimum stockholders' equity threshold of $2.5 million under Listing Rule 5550(b)(1). The Company announced on February 10, 2026 that it had received a letter from Nasdaq that the Company had regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

ESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement - has named ChicExecs as its public relations agency of record. The appointment comes as BUZZ BOMB™ gears up for a transformative year focused on aggressive brand expansion, product innovation, and a refreshed market presence.

New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®. Meclizine was the top-prescribed antiemetic/antivertigo agent in 2023, with approximately 4.09 million prescriptions.

New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform ESTERO, FL / ACCESS Newswire / February 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the appointment of Phillip Balatsos to its Board of Directors, effective February 6, 2026. The appointment follows the planned departures of Suren Ajjarapu and Donald G.

New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicines Ondansetron, currently sold under the brand name Zofran®, was the 53rd most commonly prescribed medication in the U.S. in 2023 Global ondansetron market size valued at approximately $1.4 billion in 2023 ESTERO, FL / ACCESS Newswire / February 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the filing of a provisional patent application with the United States Patent and Trademark Office (USPTO). The application, titled "A Sublingual Powder Formulation of Ondansetron and Methods of Use Thereof," marks the first-ever sublingual powder delivery system for ondansetron-the active ingredient in Zofran®.

ESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has entered into a securities purchase agreement on February 6, 2026 (the "Securities Purchase Agreement") with select institutional and accredited investors (collectively, the "Investors") for the purchase and sale of up to 26,250 shares of Series A Convertible Preferred Stock (each, a "Preferred Share" and collectively, the "Preferred Shares"), at a purchase price of $800 per Preferred Share. The Preferred Shares are convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), representing aggregate gross proceeds to the Company of up to $21.0 million, before deducting placement agent fees and other offering expenses (the "Offering").

Company achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed ESTERO, FLORIDA / ACCESS Newswire / February 10, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has received formal notice from the Listings Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company remains subject to an extension to evidence compliance with the $2.5 million stockholders' equity requirement.

ESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a proprietary sublingual caffeine supplement today announced its participation at The Sports & Active Nutrition Summit USA, scheduled for February 18-20 in San Diego, CA. Aspire will feature its flagship caffeine product, BUZZ BOMB™, at the event.